CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
2.22
2.3%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading сonditions
Spread 0.05
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Paratek Pharmaceuticals Inc ESG Risk Ratings

High Medium Low Negligible

‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 2.17
Open* 2.17
1-Year Change* -12.15%
Day's Range* 2.17 - 2.22
52 wk Range 1.29-3.65
Average Volume (10 days) 341.85K
Average Volume (3 months) 11.48M
Market Cap 127.26M
P/E Ratio -100.00K
Shares Outstanding 57.32M
Revenue 177.00M
EPS -1.11
Dividend (Yield %) N/A
Beta 1.69
Next Earnings Date Nov 1, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Sep 20, 2023 2.22 0.05 2.30% 2.17 2.22 2.17
Sep 19, 2023 2.17 0.00 0.00% 2.17 2.17 2.16
Sep 18, 2023 2.16 -0.01 -0.46% 2.17 2.18 2.16
Sep 15, 2023 2.17 -0.01 -0.46% 2.18 2.18 2.16
Sep 14, 2023 2.17 -0.01 -0.46% 2.18 2.18 2.17
Sep 13, 2023 2.18 -0.01 -0.46% 2.19 2.19 2.18
Sep 12, 2023 2.19 0.00 0.00% 2.19 2.19 2.19
Sep 11, 2023 2.18 -0.01 -0.46% 2.19 2.20 2.18
Sep 8, 2023 2.19 0.01 0.46% 2.18 2.19 2.18
Sep 7, 2023 2.19 0.01 0.46% 2.18 2.19 2.18
Sep 6, 2023 2.18 0.01 0.46% 2.17 2.19 2.17
Sep 5, 2023 2.18 0.01 0.46% 2.17 2.19 2.17
Sep 1, 2023 2.17 -0.02 -0.91% 2.19 2.20 2.17
Aug 31, 2023 2.19 0.02 0.92% 2.17 2.19 2.17
Aug 30, 2023 2.18 0.01 0.46% 2.17 2.20 2.17
Aug 29, 2023 2.18 0.01 0.46% 2.17 2.18 2.17
Aug 28, 2023 2.17 0.01 0.46% 2.16 2.18 2.16
Aug 25, 2023 2.18 0.01 0.46% 2.17 2.19 2.17
Aug 24, 2023 2.18 0.02 0.93% 2.16 2.18 2.16
Aug 23, 2023 2.16 0.00 0.00% 2.16 2.16 2.16

Paratek Pharma Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 160.268 130.162 46.924 16.544 17.117
Revenue 160.268 130.162 46.924 16.544 17.117
Total Operating Expense 206.477 171.292 124.796 132.173 121.202
Selling/General/Admin. Expenses, Total 145.398 119.004 89.355 89.135 63.658
Research & Development 37.823 30.353 23.922 39.554 57.508
Interest Expense (Income) - Net Operating 0 -0.071
Unusual Expense (Income) 0 2.368 0 0.107
Operating Income -46.209 -41.13 -77.872 -115.629 -104.085
Interest Income (Expense), Net Non-Operating -17.367 -17.342 -18.725 -12.829 -7.725
Other, Net 0.067 -0.012 0.056 -0.031 -0.044
Net Income Before Taxes -63.509 -58.484 -96.541 -128.489 -111.854
Net Income After Taxes -63.566 -59.084 -96.541 -128.79 -112.356
Net Income Before Extra. Items -63.566 -59.084 -96.541 -128.79 -112.356
Net Income -63.566 -59.084 -96.541 -128.79 -112.356
Total Adjustments to Net Income
Income Available to Common Excl. Extra. Items -63.566 -59.084 -96.541 -128.79 -112.356
Income Available to Common Incl. Extra. Items -63.566 -59.084 -96.541 -128.79 -112.356
Diluted Net Income -63.566 -59.084 -96.541 -128.79 -112.356
Diluted Weighted Average Shares 54.3879 48.4155 44.1748 32.7919 31.5135
Diluted EPS Excluding Extraordinary Items -1.16875 -1.22035 -2.18543 -3.92749 -3.56533
Diluted Normalized EPS -1.16875 -1.22035 -2.13183 -3.92749 -3.56313
Cost of Revenue, Total 23.056 21.535 8.651 3.484
Gross Profit 137.212 108.627 38.273 13.06
Depreciation / Amortization 0.2 0.4 0.5
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 39.993 31.236 75.557 30.213 29.637
Revenue 39.993 31.236 75.557 30.213 29.637
Cost of Revenue, Total 4.368 6.244 10.312 4.372 4.878
Gross Profit 35.625 24.992 65.245 25.841 24.759
Total Operating Expense 49.404 47.041 78.394 46.704 42.805
Selling/General/Admin. Expenses, Total 36.264 33.489 53.814 33.846 30.335
Research & Development 8.772 7.308 14.268 8.486 7.592
Operating Income -9.411 -15.805 -2.837 -16.491 -13.168
Interest Income (Expense), Net Non-Operating -5.035 -4.255 -4.231 -4.35 -4.413
Other, Net -0.056 -0.022 -0.032 -0.039 -0.038
Net Income Before Taxes -14.502 -20.082 -7.1 -20.88 -17.619
Net Income After Taxes -14.553 -20.143 -7.157 -20.88 -17.619
Net Income Before Extra. Items -14.553 -20.143 -7.157 -20.88 -17.619
Net Income -14.553 -20.143 -7.157 -20.88 -17.619
Income Available to Common Excl. Extra. Items -14.553 -20.143 -7.157 -20.88 -17.619
Income Available to Common Incl. Extra. Items -14.553 -20.143 -7.157 -20.88 -17.619
Diluted Net Income -14.553 -20.143 -7.157 -20.88 -17.619
Diluted Weighted Average Shares 57.2822 56.9034 55.7513 55.1665 53.0233
Diluted EPS Excluding Extraordinary Items -0.25406 -0.35399 -0.12837 -0.37849 -0.33229
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.25406 -0.35399 -0.12837 -0.37849 -0.33229
Unusual Expense (Income)
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 136.842 152.1 164.117 243.354 255.243
Cash and Short Term Investments 34.248 95.474 125.162 215.379 250.351
Cash & Equivalents 34.248 80.367 105.157 102.302 46.987
Short Term Investments 0 15.107 20.005 113.077 203.364
Total Receivables, Net 78.038 33.117 15.733 9.583 0.249
Accounts Receivable - Trade, Net 78.038 33.117 15.733 9.583 0.249
Prepaid Expenses 7.866 12.364 7.776 6.489 4.377
Other Current Assets, Total 0.125 0.125 0.891 0.324 0.266
Total Assets 172.538 183.869 176.853 251.079 300.192
Property/Plant/Equipment, Total - Net 2.398 2.551 2.974 3.741 1.173
Property/Plant/Equipment, Total - Gross 4.874 4.814 5.761 6.077 2.985
Accumulated Depreciation, Total -2.476 -2.263 -2.787 -2.336 -1.812
Goodwill, Net 0.829 0.829 0.829 0.829 0.829
Intangibles, Net 0
Other Long Term Assets, Total 32.469 28.389 8.933 3.155 0.46
Total Current Liabilities 37.388 31.297 23.953 24.2 17.709
Accounts Payable 5.308 5.394 1.813 4.116 2.09
Accrued Expenses 31.71 24.046 21.626 17.696 15.619
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 0.37 1.857 0.514 2.388
Total Liabilities 343.58 311.656 279.113 290.726 252.614
Total Long Term Debt 256.946 254.428 250.474 260.728 228.959
Long Term Debt 256.946 254.428 250.474 260.728 228.959
Other Liabilities, Total 49.246 25.931 4.686 5.798 5.946
Total Equity -171.042 -127.787 -102.26 -39.647 47.578
Preferred Stock - Non Redeemable, Net 0 0
Common Stock 0.056 0.052 0.046 0.04 0.032
Additional Paid-In Capital 759.351 739.053 705.489 671.497 630.142
Retained Earnings (Accumulated Deficit) -930.449 -866.883 -807.799 -711.258 -582.468
Other Equity, Total 0 -0.009 0.004 0.074 -0.128
Total Liabilities & Shareholders’ Equity 172.538 183.869 176.853 251.079 300.192
Total Common Shares Outstanding 56.6516 51.7118 46.5166 39.8278 32.2594
Long Term Investments 0 42.487
Total Inventory 16.565 11.02 14.555 11.579
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total Current Assets 111.014 136.842 121.341 127.768 133.282
Cash and Short Term Investments 45.026 34.248 57.009 69.391 79.053
Cash & Equivalents 45.026 34.248 27.087 39.505 49.033
Short Term Investments 0 29.922 29.886 30.02
Total Receivables, Net 37.166 78.038 32.739 31.818 28.259
Accounts Receivable - Trade, Net 37.166 78.038 32.739 31.818 28.259
Total Inventory 13.989 16.565 20.75 13.083 12.732
Prepaid Expenses 14.708 7.866 10.718 13.476 12.988
Other Current Assets, Total 0.125 0.125 0.125 0 0.25
Total Assets 150.828 172.538 157.321 163.695 170.157
Property/Plant/Equipment, Total - Net 2.24 2.398 1.791 2.064 2.298
Goodwill, Net 0.829 0.829 0.829 0.829 0.829
Other Long Term Assets, Total 36.745 32.469 33.36 33.034 33.748
Total Current Liabilities 32.745 37.388 38.976 30.1 28.837
Accounts Payable 5.318 5.308 8.107 2.257 4.697
Accrued Expenses 26.633 31.71 29.22 26.361 22.733
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 0.794 0.37 1.649 1.482 1.407
Total Liabilities 339.866 343.58 323.473 313.062 310.459
Total Long Term Debt 257.695 256.946 258.482 257.153 255.949
Long Term Debt 257.695 256.946 258.482 257.153 255.949
Other Liabilities, Total 49.426 49.246 26.015 25.809 25.673
Total Equity -189.038 -171.042 -166.152 -149.367 -140.302
Preferred Stock - Non Redeemable, Net 0 0 0 0 0
Common Stock 0.057 0.056 0.055 0.055 0.053
Additional Paid-In Capital 761.497 759.351 757.202 753.223 744.618
Retained Earnings (Accumulated Deficit) -950.592 -930.449 -923.292 -902.412 -884.793
Other Equity, Total 0 -0.117 -0.233 -0.18
Total Liabilities & Shareholders’ Equity 150.828 172.538 157.321 163.695 170.157
Total Common Shares Outstanding 57.2822 56.6516 55.4387 54.7786 53.0233
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -63.566 -59.084 -96.541 -128.79 -112.356
Cash From Operating Activities -66.141 -48.273 -103.424 -134.045 -81.179
Cash From Operating Activities 0.49 0.391 0.578
Non-Cash Items 17.726 18.609 12.825 16.483 27.254
Cash Interest Paid 11.91 13.144 22.703 15.96 9.31
Changes in Working Capital -20.791 -8.189 -20.286 -21.738 3.923
Cash From Investing Activities 14.804 4.51 92.499 134.554 -127.874
Capital Expenditures -0.036 -0.373 -0.376 -0.239 -0.06
Other Investing Cash Flow Items, Total 14.84 4.883 92.875 134.793 -127.814
Cash From Financing Activities 5.093 18.332 11.34 57.622 220.727
Financing Cash Flow Items 0.646
Issuance (Retirement) of Stock, Net 7.335 19.048 22.623 27.068 51.803
Issuance (Retirement) of Debt, Net -2.888 -0.716 -11.283 30.554 168.924
Net Change in Cash -46.244 -25.431 0.415 58.131 11.674
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -20.143 -63.566 -56.409 -35.527 -17.91
Cash From Operating Activities 11.09 -66.141 -46.028 -33.609 -19.11
Cash From Operating Activities 0.047 0.49 0.404 0.275 0.144
Non-Cash Items 3.175 17.726 14.39 9.079 3.99
Cash Interest Paid 1.934 11.91 6.779 5.739 1.181
Changes in Working Capital 28.011 -20.791 -4.413 -7.436 -5.334
Cash From Investing Activities -0.032 14.804 -15.196 -15.196 -15.196
Capital Expenditures -0.032 -0.036 -0.036 -0.036 -0.036
Other Investing Cash Flow Items, Total 0 14.84 -15.16 -15.16 -15.16
Cash From Financing Activities -0.28 5.093 7.819 7.818 3.097
Issuance (Retirement) of Stock, Net 0 7.335 7.819 7.818 3.097
Issuance (Retirement) of Debt, Net -0.28 -2.888 0 0 0
Net Change in Cash 10.778 -46.244 -53.405 -40.987 -31.209
Financing Cash Flow Items 0.646

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Paratek Pharma Company profile

About Paratek Pharmaceuticals Inc

Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel life-saving therapies for life-threatening diseases. The Company's product include NUZYRA (omadacycline) is an oral and intravenous antibiotic for the treatment of community-acquired bacterial pneumonia and acute skin and skin structure infections caused by susceptible pathogens. Its other product includes SEYSARA, which is a oral therapy for the treatment of moderate to severe acne vulgaris.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Paratek Pharmaceuticals Inc revenues increased from $46.9M to $130.2M. Net loss decreased 39% to $59.1M. Revenues reflect Product revenue, net increase from $38.8M to $106.1M, Collaboration and royalty revenue increase from $1.5M to $8.2M, Government contract grant revenue increase from $3.4M to $9.2M. Lower net loss reflects Interest Expense decrease of 14% to $17.4M (expense).

Equity composition

Common Stock $.001 Par, 3/11, 100M auth., 13,467,933 issd. Insiders control 9.22%. IPO: 5/06 .3M shs. @ $6.50 per share by Bear, Stearns & Co. Inc. 02/09, Name changed from Novacea, Inc. 02/09, 5-for-1 reverse stock split. 10/14,1-for-12 reverse stock split.

Industry: Pharmaceuticals (NEC)

75 Park Plaza
4th Floor
BOSTON
MASSACHUSETTS 02116
US

Income Statement

  • Annual
  • Quarterly

News

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

Higher CPI leaves traders unfazed as US equities continue to build momentum

The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

12:42, 15 March 2024

Four reasons why Bitcoin is surging to record highs

Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.

10:18, 14 March 2024

China’s National People’s Congress: The markets have again been left wanting more

China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.

08:23, 8 March 2024
Facade on the Federal Reserve Building in Washington DC

Central Banks: which one will cut first?

Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut

13:14, 6 March 2024

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

UK Bank Earnings: What to expect from Lloyds, Barclays and HSBC?

UK banks will be in the spotlight in the week ahead as the European earnings season continues

16:38, 16 February 2024

People also watch

Oil - Crude

82.20 Price
-0.080% 1D Chg, %
Long position overnight fee 0.0269%
Short position overnight fee -0.0488%
Overnight fee time 22:00 (UTC)
Spread 0.030

US100

17,981.30 Price
+0.000% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 1.8

Gold

2,153.38 Price
-0.330% 1D Chg, %
Long position overnight fee -0.0188%
Short position overnight fee 0.0106%
Overnight fee time 22:00 (UTC)
Spread 0.30

XRP/USD

0.59 Price
-4.530% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading